A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
A phase 1/2 trial of GSK5460025 in colorectal cancer, run by GlaxoSmithKline, now recruiting.
Overview
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors is a phase 1/2 interventional study registered as NCT07213609 by GlaxoSmithKline, with 47 participants planned, started 2025-10-20 and due to reach its primary completion in 2028-09-28. Interventions recorded: GSK5460025.
Similar pages
not linked directly; found by shared links- TrialStudy of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
Shares GSK, Colorectal cancer and the tag pipeline.
- TrialA Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer
Shares GSK, Colorectal cancer and the tag pipeline.
- TrialA Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China
Shares GSK, Colorectal cancer and the tag pipeline.
- TrialA Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
Shares GSK and the tag pipeline.
- TrialFirst-Time-in-Human Study of GSK5471713 in Adults With mCRPC
Shares GSK and the tag pipeline.
- TrialA Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
Shares GSK and the tag pipeline.
- TrialA Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)
Shares GSK and the tag pipeline.
- TrialA Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Shares GSK, Colorectal cancer and the tag pipeline.